Cross-contamination is an inherent problem in culturing Drug susceptibility testing mycobacteria.
1,2 Unrecognized cross-contamination has been known to occur in laboratories frequently, especially with Antimycobacterial drug susceptibility of all the specimens sensitive recovery system like BACTEC 460 TB system. 3 The was determined by BACTEC 460 TB system. potential impact of cross contamination results in false Spoligotyping positive cultures which may lead to needless therapy with all Spoligotyping was performed with a commercially available kit (Isogen Bioscience). Briefly, the procedure involved We report use of spoligotyping to confirm our suspicion amplification of the direct repeat (DR) region of M. that cross-contamination had occurred in our mycobacteriology tuberculosis genome by polymerase chain reaction using laboratory, in the year 2001 and use of procedures such as specific biotinylated primers. 5 The amplified products were dedicated decontamination for limiting such future instances.
then hybridized onto a nylon membrane blotted with 43 spacer Materials and Methods sequences. The spacer sequences were specific to the DR region and the strains differed in presence or absence of these The mycobacteriology laboratory at PD Hinduja National spacer sequences. The results of hybridization were detected Hospital and Medical Research Center, Mumbai, India, receives by ECL detection system. 6, 7 about 3500 requests for acid-fast bacteria cultures annually, 45% of which are positive for M. tuberculosis complex. All the RFLP analysis specimens we receive are decontaminated by standard NALC-RFLP analysis was performed by the internationally its problems.
NaOH method 4 and then inoculated into BACTEC 12 B vial along with one Lowenstein & Jensen (L.J) slant.
In this episode, suspected cross contamination cases were confirmed by antimycobacterial drug susceptibility patterns, spoligotyping and restriction fragment length polymorphism (RFLP). standardized procedure. 7 In brief, bacterial cell walls were lysed and whole genomic DNA was extracted and digested with PvuII. The resulting DNA fingerprints were separated by gel electrophoresis, transferred to nylon membrane and probed with a horseradish peroxidase-labeled 245-bp sequence of IS6110 DNA.
Clinical correlation
The medical records of all six patients were reviewed and the treating physicians were contacted for clinical details. The laboratory technician was interviewed to obtain information about specimen handling and processing. Confidentiality of all reports was maintained.
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Results
A retrospective investigation was carried out after receiving the feedback of a report of M. tuberculosis complex in a patient not clinically suspected to have tuberculosis (TB). Review of laboratory records revealed that of the nine consecutive specimens processed in the same batch, six were positive by culture (Table 1) . Of these six specimens, three were acid-fast bacilli (AFB) negative in smears, which included a urine sample, a bronchoalveolar lavage and a pus sample. All these three cultures were positive only in the BACTEC bottles almost after three weeks and yielded no growth on the accompanying LJ slants. Clinical findings for these three patients were not consistent with active TB. The drug human or technical errors that occur in the laboratory while processing clinical specimens. The last category can be caused by batch processing, laboratory protocols not adapted for lefthandedness, 8,9 sleeve of the laboratory coats of technicians touching the tubes, use of common decontamination reagents and phosphate buffer, use of a faulty exhaust hood, soiled needles or faulty needle heater circuit in the BACTEC 460 TB system. 1, 3, 8, 10 In this series, all the specimens were processed in the biological safety cabinet class II by general laboratory technician. However, the order of processing was neither according to the accession number nor in the ascending order of bacterial load. The AFB smear positive sputum samples All the six M. tuberculosis isolates were subjected to spoligotyping. Result analysis showed the identical spoligopatterns in four out of six M. tuberculosis isolates. Review of laboratory records revealed that, of the four clinical specimens showing identical spoligotypes, one was smear positive and considered to be the index specimen. Remaining two isolates grown from smear positive specimens had different spoligotypes hence were considered true positives.
Since spoligotyping is known to be less refractory for differentiation of M. tuberculosis, we also analyzed the strains using IS6110 RFLP analysis. However, only three strains (index specimen and two contaminated specimens) could be typed using RFLP due to lack of availability of adequate or good quality DNA. All these three specimens typed showed same RFLP pattern indicated by a single band.
Review of literature reveals a large variation in the reported rates of cross-contamination, ranging from 0.1 to 65%. 8 Multiple factors can contribute to cross contamination, including contaminated clinical devices, clerical errors and were processed before the smear negative samples. Further investigation suggested that the cross-contamination probably resulted while dispensing decontamination reagents and neutralizing agent [phosphate buffered saline (PBS)] with a common flask. PBS was prepared in a liter quantity and the contamination might have occurred due to unintentional touching the edges of the open specimen containing tubes with the PBS flask or droplets splashed from a sample in a specimen containing tube while pouring PBS directly through the heavy flask. Since this pseudo-outbreak was recorded almost three weeks after the inoculation, the original decontamination reagents and phosphate buffer were not available for culture.
Recognition of laboratory cross-contamination and elucidation of its probable cause has resulted in the revision of laboratory procedures. Instead of using general laboratory technicians, we have two full-time, thoroughly trained and experienced TB-technician dedicated to mycobacteriology. In addition two more technicians are trained for emergency back up. To avoid cross-contamination we have devised a dedicated decontamination procedure for decontamination as given below:
1. Separate aliquoting of PBS and decontamination reagents per patient. All the decontamination reagents i.e., N acetyl -L -cysteine solution, 4% NaOH, 2.9% Na -citrate, 0.067 M Phosphate buffer ph 6.8 are freshly prepared daily and aliquoted in a smaller glass containers, autoclaved and then bar-coded with patient's identification. As all these containers can be washed, autoclaved and reused, the method is cost-effective.
2. All specimens obtained from sterile body sites are centrifuged and cultured without decontamination.
3. We ensure that the order of specimens processing is from low bacterial load to high bacterial load. Extrapulmonary specimens especially cerebrospinal fluid (CSF) are always
